Product Code: ETC7655384 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 | |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Israel Mantle Cell Lymphoma Market Overview |
3.1 Israel Country Macro Economic Indicators |
3.2 Israel Mantle Cell Lymphoma Market Revenues & Volume, 2021 & 2031F |
3.3 Israel Mantle Cell Lymphoma Market - Industry Life Cycle |
3.4 Israel Mantle Cell Lymphoma Market - Porter's Five Forces |
3.5 Israel Mantle Cell Lymphoma Market Revenues & Volume Share, By Drugs, 2021 & 2031F |
4 Israel Mantle Cell Lymphoma Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence and incidence of mantle cell lymphoma in Israel |
4.2.2 Advancements in diagnostic technologies and treatment options for mantle cell lymphoma |
4.2.3 Growing awareness and focus on personalized medicine and targeted therapies in oncology |
4.3 Market Restraints |
4.3.1 High cost associated with novel treatments for mantle cell lymphoma |
4.3.2 Limited access to specialized healthcare facilities and expertise for managing mantle cell lymphoma cases in Israel |
5 Israel Mantle Cell Lymphoma Market Trends |
6 Israel Mantle Cell Lymphoma Market, By Types |
6.1 Israel Mantle Cell Lymphoma Market, By Drugs |
6.1.1 Overview and Analysis |
6.1.2 Israel Mantle Cell Lymphoma Market Revenues & Volume, By Drugs, 2021- 2031F |
6.1.3 Israel Mantle Cell Lymphoma Market Revenues & Volume, By Revlimid (Lenalidomide), 2021- 2031F |
6.1.4 Israel Mantle Cell Lymphoma Market Revenues & Volume, By Tecartus (Brexucabtagene autoleucel), 2021- 2031F |
6.1.5 Israel Mantle Cell Lymphoma Market Revenues & Volume, By Brukinsa (Zanubrutinib), 2021- 2031F |
6.1.6 Israel Mantle Cell Lymphoma Market Revenues & Volume, By Imbruvica (Ibrutinib), 2021- 2031F |
6.1.7 Israel Mantle Cell Lymphoma Market Revenues & Volume, By Calquence (Acalabrutinib), 2021- 2031F |
6.1.8 Israel Mantle Cell Lymphoma Market Revenues & Volume, By Abemaciclib, 2021- 2031F |
6.1.9 Israel Mantle Cell Lymphoma Market Revenues & Volume, By Elimusertib, 2021- 2031F |
6.1.10 Israel Mantle Cell Lymphoma Market Revenues & Volume, By Elimusertib, 2021- 2031F |
7 Israel Mantle Cell Lymphoma Market Import-Export Trade Statistics |
7.1 Israel Mantle Cell Lymphoma Market Export to Major Countries |
7.2 Israel Mantle Cell Lymphoma Market Imports from Major Countries |
8 Israel Mantle Cell Lymphoma Market Key Performance Indicators |
8.1 Average time from diagnosis to initiation of treatment for mantle cell lymphoma patients in Israel |
8.2 Percentage of mantle cell lymphoma patients receiving targeted therapies or personalized medicine |
8.3 Survival rates of mantle cell lymphoma patients in Israel |
8.4 Number of clinical trials focused on mantle cell lymphoma treatments conducted in Israel |
8.5 Adoption rate of new treatment guidelines for mantle cell lymphoma in Israeli healthcare institutions |
9 Israel Mantle Cell Lymphoma Market - Opportunity Assessment |
9.1 Israel Mantle Cell Lymphoma Market Opportunity Assessment, By Drugs, 2021 & 2031F |
10 Israel Mantle Cell Lymphoma Market - Competitive Landscape |
10.1 Israel Mantle Cell Lymphoma Market Revenue Share, By Companies, 2024 |
10.2 Israel Mantle Cell Lymphoma Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |